Manufacturing
We have the unique capability to leverage multiple manufacturing facilities for our research and development and commercial manufacturing activities.
We have the unique capability to leverage multiple manufacturing facilities for our research and development and commercial manufacturing activities.
We have two in-house manufacturing facilities: a good manufacturing practice (GMP)-certified commercial manufacturing in Changxing, Zhejiang province, China, and a research and development and pilot manufacturing facility in Chengdu, Sichuan province, China. In addition, we have partnered with a contract development and manufacturing organization facility with European Union GMP certification to bolster our ability to flexibly supply our COVID-19 vaccine to meet demand in China and globally.
Our in-house, commercial-ready vaccines manufacturing facility in Changxing, Zhejiang province has achieved good manufacturing practice status for the production of SCB-2019 (CpG 1018/Alum) in China and is now supporting the commercial production of SCB-2019 (CpG 1018/Alum).
Located in Chengdu, Sichuan province, our R&D and pilot manufacturing facility supplies materials for our pre-clinical and early-stage clinical trials. It occupies approximately 3,300 square meters and contains a 200 liter single-use and 150 liter stainless steel bioreactor capacity as well as multiple pilot-scale drug product filling lines.
